immune-checkpoint-inhibitors

Documents about immune-checkpoint-inhibitors

• Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types#140164Unpaywall
• Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)#444883ClinicalTrials.gov
• The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis#676304Europe PMC
• Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma#811889ClinicalTrials.gov
• A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors#902710ClinicalTrials.gov
• Baseline C-reactive protein independently predicts treatment response and survival in metastatic melanoma patients receiving first-line immune checkpoint inhibitors#1028844Bielefeld Pub
• Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients#874427ClinicalTrials.gov
• Immune checkpoint inhibitors in children with replication-repair-deficient high-grade gliomas. The South London Paediatric & TYA Neuro-Oncology Network experience#4876Europe PMC
• Association between the Prognostic Nutritional Index and survival outcomes in hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.#368060NCBI PubMed Central
• Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population#373587ClinicalTrials.gov
• Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors#451408ClinicalTrials.gov
• Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC#879807ClinicalTrials.gov
• Table 1_Global research trends and emerging frontiers of intratumoral microbiota in cancer immunotherapy: a bibliometric and visualization analysis.docx#384349Figshare
• R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors#908775ClinicalTrials.gov
• The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis#464131Figshare
• The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)#174856ClinicalTrials.gov
• Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors#178205HAL (France)
• Tigit And Gdf-15 As Biomarkers And Targets In Renal Cell Carcinoma Resistant To Immune Checkpoint Inhibitors#260915EliScholar
• The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy#280409HAL (France)
• Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study#439915Springer Nature OA
• A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients#444886ClinicalTrials.gov
• Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up#465446OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)#801440ClinicalTrials.gov
• AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma#852431ClinicalTrials.gov
• Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP#864493ClinicalTrials.gov
• Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer#881968ClinicalTrials.gov
• Naltrexone and Propranolol Combined With Immunotherapy#892860ClinicalTrials.gov
• Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients#896478ClinicalTrials.gov
• Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma#913896ClinicalTrials.gov
• More than age: Impact of comorbidity and polypharmacy on immune-related adverse events, treatment discontinuation, and toxicity management in older patients receiving immune checkpoint inhibitors / Anja Gesierich, Eran Demeter, Bastian Schilling, Barbara Deschler-Baier#1015032Deutsche Nationalbibliothek
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors#148776ClinicalTrials.gov
• Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial#628521ClinicalTrials.gov
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.#979394ClinicalTrials.gov
• Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors#1053160Europe PMC
• A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma#827885ClinicalTrials.gov
• Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer#880806ClinicalTrials.gov
• Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis#465418ODU Digital Commons
• Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors#845785ClinicalTrials.gov
• Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma#911900ClinicalTrials.gov
• Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer#982117ClinicalTrials.gov
• A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.#143556ClinicalTrials.gov
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)#279487ClinicalTrials.gov
• Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer#377424ClinicalTrials.gov
• Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy#140999ClinicalTrials.gov
• Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications#308335HAL (France)
• The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?#215411HAL (France)
• Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis#936032Repositorio de Universidad Autónoma de Chile.
• Gut Microbiota (GM) Biodiversity in Patients With Solid Tumors Treated With Immune Checkpoint Inhibitors (ICIs): a Monocenter Prospective Study to Identify the Interactions Between GM and ICIs#307436ClinicalTrials.gov
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma#891611ClinicalTrials.gov
• Table 1_Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy.docx#210838Figshare